Nemaura Medical Inc. (NMRD)
| Market Cap | 40.00 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.65M |
| Shares Out | 40.35M |
| EPS (ttm) | -0.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 325 |
| Open | 0.0002 |
| Previous Close | n/a |
| Day's Range | 0.0002 - 0.0002 |
| 52-Week Range | 0.0001 - 0.2540 |
| Beta | -0.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 11, 2025 |
About Nemaura Medical
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based ... [Read more]
Financial Performance
In 2022, Nemaura Medical's revenue was $77,044, a decrease of -84.71% compared to the previous year's $503,906. Losses were -$14.14 million, 1.85% more than in 2021.
Financial StatementsNews
Important Update on Listing Status and Strategic Direction
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, i...
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthc...
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthc...
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
Company CEO to discuss development at 1pm EST on 15 th November 2023, at the Sidoti Virtual Investor Conference
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a dai...
Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.
LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive w...
Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference
Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic ...
Nemaura Medical Provides Update on Nasdaq Compliance Status and Process
LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive w...
Nemaura Medical Announces Interim Results from its Collaboration with the UK's National Health Service on its Metabolic Health & Weight Loss Program
LOUGHBOROUGH, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive w...
Nemaura Medical Announces Participation at HLTH 2023, Las Vegas
LOUGHBOROUGH, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive w...
Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results
LOUGHBOROUGH, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive ...
Nemaura Medical Announces SFDA Approval of sugarBEAT®
Loughborough, England, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a dai...
Nemaura Medical Secures $6.5m in Non-Dilutive Funding
Loughborough, England, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and su...
Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023
Loughborough, England, July 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a dai...
Nemaura Medical to Participate in Fireside Chat Hosted by EF Hutton
LOUGHBOROUGH, March 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive...
Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement
LOUGHBOROUGH, March 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive...
Nemaura Medical Announces Receipt of Notice from Nasdaq
LOUGHBOROUGH, March 09, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive w...
Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update
Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-i...
Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference
Loughborough, England, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable sensors and ...
Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
LOUGHBOROUGH, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive w...
Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
LOUGHBOROUGH, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive w...
Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable...
Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable...
Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference
Loughborough, England, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic de...
Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022
Loughborough, England, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic de...